vs
Leonardo DRS, Inc.（DRS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Leonardo DRS, Inc.的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs 9.6%，领先3.1%），Leonardo DRS, Inc.同比增速更快（8.1% vs 5.9%），Leonardo DRS, Inc.自由现金流更多（$376.0M vs $161.8M），过去两年Leonardo DRS, Inc.的营收复合增速更高（24.1% vs 9.0%）
莱昂纳多DRS公司是美国本土国防承包商，前身为DRS技术公司，曾于纽约证券交易所挂牌交易，2008年被莱昂纳多的前身芬梅卡尼卡收购，核心业务为向美国军方提供先进国防技术及配套系统产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DRS vs RVTY — 直观对比
营收规模更大
DRS
是对方的1.4倍
$772.1M
营收增速更快
DRS
高出2.2%
5.9%
净利率更高
RVTY
高出3.1%
9.6%
自由现金流更多
DRS
多$214.2M
$161.8M
两年增速更快
DRS
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $102.0M | $98.4M |
| 毛利率 | 25.4% | — |
| 营业利润率 | 11.9% | 14.5% |
| 净利率 | 9.6% | 12.7% |
| 营收同比 | 8.1% | 5.9% |
| 净利润同比 | 14.6% | 3.9% |
| 每股收益（稀释后） | $0.38 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DRSRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $960.0M | $698.9M | ||
| Q2 25 | $829.0M | $720.3M | ||
| Q1 25 | $799.0M | $664.8M | ||
| Q4 24 | $981.0M | $729.4M | ||
| Q3 24 | $812.0M | $684.0M | ||
| Q2 24 | $753.0M | $691.7M | ||
| Q1 24 | $688.0M | $649.9M |
净利润DRSRVTY
| Q4 25 | $102.0M | $98.4M | ||
| Q3 25 | $72.0M | $46.7M | ||
| Q2 25 | $54.0M | $53.9M | ||
| Q1 25 | $50.0M | $42.2M | ||
| Q4 24 | $89.0M | $94.6M | ||
| Q3 24 | $57.0M | $94.4M | ||
| Q2 24 | $38.0M | $55.4M | ||
| Q1 24 | $29.0M | $26.0M |
毛利率DRSRVTY
| Q4 25 | 25.4% | — | ||
| Q3 25 | 23.1% | 53.6% | ||
| Q2 25 | 23.8% | 54.5% | ||
| Q1 25 | 22.7% | 56.5% | ||
| Q4 24 | 24.0% | — | ||
| Q3 24 | 22.0% | 56.3% | ||
| Q2 24 | 22.4% | 55.7% | ||
| Q1 24 | 22.2% | 54.6% |
营业利润率DRSRVTY
| Q4 25 | 11.9% | 14.5% | ||
| Q3 25 | 9.7% | 11.7% | ||
| Q2 25 | 8.4% | 12.6% | ||
| Q1 25 | 7.4% | 10.9% | ||
| Q4 24 | 12.2% | 16.3% | ||
| Q3 24 | 9.2% | 14.3% | ||
| Q2 24 | 7.3% | 12.4% | ||
| Q1 24 | 6.3% | 6.8% |
净利率DRSRVTY
| Q4 25 | 9.6% | 12.7% | ||
| Q3 25 | 7.5% | 6.7% | ||
| Q2 25 | 6.5% | 7.5% | ||
| Q1 25 | 6.3% | 6.4% | ||
| Q4 24 | 9.1% | 13.0% | ||
| Q3 24 | 7.0% | 13.8% | ||
| Q2 24 | 5.0% | 8.0% | ||
| Q1 24 | 4.2% | 4.0% |
每股收益（稀释后）DRSRVTY
| Q4 25 | $0.38 | $0.86 | ||
| Q3 25 | $0.26 | $0.40 | ||
| Q2 25 | $0.20 | $0.46 | ||
| Q1 25 | $0.19 | $0.35 | ||
| Q4 24 | $0.34 | $0.77 | ||
| Q3 24 | $0.21 | $0.77 | ||
| Q2 24 | $0.14 | $0.45 | ||
| Q1 24 | $0.11 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $647.0M | $919.9M |
| 总债务越低越好 | $321.0M | — |
| 股东权益账面价值 | $2.7B | $7.3B |
| 总资产 | $4.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资DRSRVTY
| Q4 25 | $647.0M | $919.9M | ||
| Q3 25 | $309.0M | $931.4M | ||
| Q2 25 | $278.0M | $991.8M | ||
| Q1 25 | $380.0M | $1.1B | ||
| Q4 24 | $598.0M | $1.2B | ||
| Q3 24 | $198.0M | $1.2B | ||
| Q2 24 | $149.0M | $2.0B | ||
| Q1 24 | $160.0M | $1.7B |
总债务DRSRVTY
| Q4 25 | $321.0M | — | ||
| Q3 25 | $326.0M | — | ||
| Q2 25 | $331.0M | — | ||
| Q1 25 | $335.0M | — | ||
| Q4 24 | $340.0M | — | ||
| Q3 24 | $345.0M | — | ||
| Q2 24 | $351.0M | — | ||
| Q1 24 | $356.0M | — |
股东权益DRSRVTY
| Q4 25 | $2.7B | $7.3B | ||
| Q3 25 | $2.6B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.6B | $7.6B | ||
| Q4 24 | $2.6B | $7.7B | ||
| Q3 24 | $2.5B | $7.9B | ||
| Q2 24 | $2.4B | $7.9B | ||
| Q1 24 | $2.4B | $7.8B |
总资产DRSRVTY
| Q4 25 | $4.5B | $12.2B | ||
| Q3 25 | $4.2B | $12.1B | ||
| Q2 25 | $4.1B | $12.4B | ||
| Q1 25 | $4.1B | $12.4B | ||
| Q4 24 | $4.2B | $12.4B | ||
| Q3 24 | $3.9B | $12.8B | ||
| Q2 24 | $3.8B | $13.4B | ||
| Q1 24 | $3.8B | $13.4B |
负债/权益比DRSRVTY
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $425.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $376.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 35.5% | 21.0% |
| 资本支出强度资本支出/营收 | 4.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 4.17× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $227.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流DRSRVTY
| Q4 25 | $425.0M | $182.0M | ||
| Q3 25 | $107.0M | $138.5M | ||
| Q2 25 | $-28.0M | $134.3M | ||
| Q1 25 | $-138.0M | $128.2M | ||
| Q4 24 | $443.0M | $174.2M | ||
| Q3 24 | $59.0M | $147.9M | ||
| Q2 24 | $34.0M | $158.6M | ||
| Q1 24 | $-265.0M | $147.6M |
自由现金流DRSRVTY
| Q4 25 | $376.0M | $161.8M | ||
| Q3 25 | $77.0M | $120.0M | ||
| Q2 25 | $-56.0M | $115.5M | ||
| Q1 25 | $-170.0M | $112.2M | ||
| Q4 24 | $414.0M | $149.8M | ||
| Q3 24 | $47.0M | $125.6M | ||
| Q2 24 | $0 | $136.6M | ||
| Q1 24 | $-275.0M | $129.7M |
自由现金流率DRSRVTY
| Q4 25 | 35.5% | 21.0% | ||
| Q3 25 | 8.0% | 17.2% | ||
| Q2 25 | -6.8% | 16.0% | ||
| Q1 25 | -21.3% | 16.9% | ||
| Q4 24 | 42.2% | 20.5% | ||
| Q3 24 | 5.8% | 18.4% | ||
| Q2 24 | 0.0% | 19.7% | ||
| Q1 24 | -40.0% | 20.0% |
资本支出强度DRSRVTY
| Q4 25 | 4.6% | 2.6% | ||
| Q3 25 | 3.1% | 2.6% | ||
| Q2 25 | 3.4% | 2.6% | ||
| Q1 25 | 4.0% | 2.4% | ||
| Q4 24 | 3.0% | 3.4% | ||
| Q3 24 | 1.5% | 3.3% | ||
| Q2 24 | 4.5% | 3.2% | ||
| Q1 24 | 1.5% | 2.7% |
现金转化率DRSRVTY
| Q4 25 | 4.17× | 1.85× | ||
| Q3 25 | 1.49× | 2.97× | ||
| Q2 25 | -0.52× | 2.49× | ||
| Q1 25 | -2.76× | 3.03× | ||
| Q4 24 | 4.98× | 1.84× | ||
| Q3 24 | 1.04× | 1.57× | ||
| Q2 24 | 0.89× | 2.87× | ||
| Q1 24 | -9.14× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DRS
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
